InsightfulValue
← Home

GlaxoSmithKline
GlaxoSmithKline

Pharma / Pharma and biotechnology


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

GlaxoSmithKline

πŸ“Š Get full analytics about GlaxoSmithKline

Sign up for free or log in

✍️ Sign up to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" for free

Price
Live  
Overview
GlaxoSmithKline (GSK) is a multinational pharmaceutical and healthcare company headquartered in Brentford, London. The company was formed in 2000 through the merger of British company Glaxo Wellcome and American company SmithKline Beecham. It is one of the largest pharmaceutical companies in the world and is focused on the research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products.
History:
The history of GlaxoSmithKline can be traced back to the establishment of two independent companies: Joseph Nathan and Co. in New Zealand in 1873 and Burroughs Wellcome & Company in the UK in 1880. In 1995, Glaxo Wellcome PLC was formed through the merger of Glaxo and Burroughs Wellcome. SmithKline Beecham PLC was formed in 1989 through the merger of SmithKline Beckman Corporation and Beecham Group PLC. In 2000, the two companies merged to form GlaxoSmithKline.
Products:
GSK's product portfolio includes prescription medicines, vaccines, and consumer healthcare products. Its prescription medicines cover a broad range of therapeutic areas, including respiratory, HIV, oncology, and neurosciences. The company also offers vaccines for diseases such as influenza, meningitis, and shingles. Its consumer healthcare products include over-the-counter medicines, oral care, nutrition, and skin health products.
Research and Development:
GSK has a strong focus on research and development (R&D) and invests heavily in this area. The company has R&D facilities in the UK, US, Belgium, and China, among others. Its R&D efforts are focused on discovering and developing new medicines and vaccines for a wide range of diseases and conditions. GSK collaborates with academic institutions, governments, and other industry partners to advance its research efforts.
Corporate Responsibility:
GSK is committed to operating ethically and responsibly, with a focus on sustainability and corporate social responsibility. The company has various initiatives in place to reduce its environmental impact and improve access to healthcare for underserved populations. It also has policies in place to ensure ethical business practices and compliance with laws and regulations.
Financials:
In 2020, GSK reported revenues of Β£34 billion and a net income of Β£5.5 billion. The company employs over 100,000 people globally and has a presence in over 150 countries. Its primary stock exchange listings are on the London Stock Exchange and the New York Stock Exchange.
Partnerships:
GSK has formed partnerships with various organizations to further its research and development efforts, expand its product portfolio, and improve access to healthcare. Some notable collaborations include:
- Joint ventures with Pfizer in the areas of consumer healthcare and HIV treatment
- Collaboration with Sanofi to develop a COVID-19 vaccine
- Partnership with Innoviva to develop respiratory treatments
- Collaboration with Vir Biotechnology to develop pandemic treatments
- Partnership with the Bill & Melinda Gates Foundation to develop vaccines for malaria and tuberculosis
Summary:
GlaxoSmithKline is a multinational pharmaceutical and healthcare company focused on research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products. It has a strong history and presence in the market, with a commitment to corporate responsibility and ethical business practices. The company has a diverse range of products and partnerships that contribute to its strong financial performance.
What is special about the company?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

⚑ Instantly access "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

VGhlcmUgYX JlIHNldmVy YWwga2V5IG ZhY3RvcnMg dGhhdCBtYW tlIEdsYXhv U21pdGhLbG luZSAoR1NL KSBhIHVuaX F1ZSBhbmQg c3BlY2lhbC Bjb21wYW55 Ojxicj4xLi BTaXplIGFu ZCBTY29wZT ogR1NLIGlz IG9uZSBvZi B0aGUgbGFy Z2VzdCBwaG FybWFjZXV0 aWNhbCBjb2 1wYW5pZXMg aW4gdGhlIH dvcmxkLCB3 aXRoIG9wZX JhdGlvbnMg aW4gb3Zlci AxNTAgY291 bnRyaWVzIG FuZCBhIHZh c3QgcG9ydG ZvbGlvIG9m IHByb2R1Y3 RzIHNwYW5u aW5nIHByZX NjcmlwdGlv biBtZWRpY2 luZXMsIGNv bnN1bWVyIG hlYWx0aGNh cmUsIGFuZC B2YWNjaW5l cy48YnI+Mi 4gSGlzdG9y eSBhbmQgTG VnYWN5OiBH U0sgaGFzIG EgcmljaCBo aXN0b3J5IG RhdGluZyBi YWNrIHRvIH RoZSAxOXRo IGNlbnR1cn ksIHdpdGgg dGhlIG1lcm dlciBvZiBH bGF4b1dlbG xjb21lIGFu ZCBTbWl0aE tsaW5lIEJl ZWNoYW0gaW 4gMjAwMCBz b2xpZGlmeW luZyBpdHMg cG9zaXRpb2 4gYXMgYSBt YWpvciBwbG F5ZXIgaW4g dGhlIGhlYW x0aGNhcmUg aW5kdXN0cn kuPGJyPjMu IFJlc2Vhcm NoIGFuZCBE ZXZlbG9wbW VudDogSW5u b3ZhdGlvbi BhbmQgcmVz ZWFyY2ggYX JlIGF0IHRo ZSBoZWFydC BvZiBHU0sn cyBidXNpbm Vzcywgd2l0 aCBzaWduaW ZpY2FudCBp bnZlc3RtZW 50cyBtYWRl IGluIGRpc2 NvdmVyaW5n IGFuZCBkZX ZlbG9waW5n IG5ldyBtZW RpY2luZXMg dG8gbWVldC B1bm1ldCBt ZWRpY2FsIG 5lZWRzLjxi cj40LiBDb2 1taXRtZW50 IHRvIEdsb2 JhbCBIZWFs dGg6IEdTSy dzIG1pc3Np b24gaXMgdG 8gaW1wcm92 ZSB0aGUgcX VhbGl0eSBv ZiBodW1hbi BsaWZlIGJ5 IGVuYWJsaW 5nIHBlb3Bs ZSB0byBkby Btb3JlLCBm ZWVsIGJldH RlciwgYW5k IGxpdmUgbG 9uZ2VyLiBU aGUgY29tcG FueSBpcyBk ZWRpY2F0ZW QgdG8gYWRk cmVzc2luZy BnbG9iYWwg aGVhbHRoIG NoYWxsZW5n ZXMsIHN1Y2 ggYXMgaW5m ZWN0aW91cy BkaXNlYXNl cyBhbmQgYW NjZXNzIHRv IGhlYWx0aG NhcmUgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMuPG JyPjUuIERp dmVyc2UgUG 9ydGZvbGlv OiBHU0sgaG FzIGEgZGl2 ZXJzZSBwb3 J0Zm9saW8g b2YgcHJvZH VjdHMsIGlu Y2x1ZGluZy BtYXJrZXQt bGVhZGluZy BicmFuZHMg c3VjaCBhcy BBZHZhaXIs IFNlbnNvZH luZSwgYW5k IEZsb25hc2 UuIEl0IGFs c28gaGFzIG Egc3Ryb25n IHBpcGVsaW 5lIG9mIHBv dGVudGlhbC BuZXcgbWVk aWNpbmVzIG FuZCB2YWNj aW5lcyBpbi B2YXJpb3Vz IHN0YWdlcy BvZiBkZXZl bG9wbWVudC 48YnI+Ni4g Q29ycG9yYX RlIFJlc3Bv bnNpYmlsaX R5OiBHU0sg aXMgY29tbW l0dGVkIHRv IGNvbmR1Y3 RpbmcgYnVz aW5lc3Mgcm VzcG9uc2li bHkgYW5kIG V0aGljYWxs eSwgd2l0aC BhIGZvY3Vz IG9uIHN1c3 RhaW5hYmls aXR5LCBlbn Zpcm9ubWVu dGFsIHN0ZX dhcmRzaGlw LCBhbmQgaW 1wcm92aW5n IGFjY2Vzcy B0byBoZWFs dGhjYXJlIG ZvciB1bmRl cnNlcnZlZC Bwb3B1bGF0 aW9ucy48Yn I+Ny4gQ3Vs dHVyZSBhbm QgVmFsdWVz OiBHU0sgcH JpZGVzIGl0 c2VsZiBvbi BpdHMgZGl2 ZXJzZSBhbm QgaW5jbHVz aXZlIHdvcm twbGFjZSBj dWx0dXJlLC BndWlkZWQg YnkgYSBzZX Qgb2YgY29y ZSB2YWx1ZX MgdGhhdCBw cmlvcml0aX plIGludGVn cml0eSwgcm VzcGVjdCBm b3IgcGVvcG xlLCBhbmQg dHJhbnNwYX JlbmN5Ljxi cj5PdmVyYW xsLCBHU0sn cyBzaXplLC BoaXN0b3J5 LCBmb2N1cy BvbiBpbm5v dmF0aW9uIG FuZCBnbG9i YWwgaGVhbH RoLCBkaXZl cnNlIHBvcn Rmb2xpbywg Y29tbWl0bW VudCB0byBj b3Jwb3JhdG UgcmVzcG9u c2liaWxpdH ksIGFuZCBz dHJvbmcgY3 VsdHVyZSBt YWtlIGl0IG EgdW5pcXVl IGFuZCBlc3 RlZW1lZCBj b21wYW55IG luIHRoZSBw aGFybWFjZX V0aWNhbCBp bmR1c3RyeS 4=
What the company's business model?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

R2xheG9TbW l0aEtsaW5l IChHU0spIG lzIGEgZ2xv YmFsIHBoYX JtYWNldXRp Y2FsIGFuZC BoZWFsdGhj YXJlIGNvbX BhbnkgZm9j dXNlZCBvbi BpbXByb3Zp bmcgdGhlIG hlYWx0aCBh bmQgd2VsbC 1iZWluZyBv ZiBwZW9wbG UgYXJvdW5k IHRoZSB3b3 JsZC4gVGhl IGNvbXBhbn kncyBidXNp bmVzcyBtb2 RlbCBpcyBi YXNlZCBvbi Bmb3VyIGtl eSBjb21wb2 5lbnRzOiA8 YnI+MS4gUm VzZWFyY2gg YW5kIERldm Vsb3BtZW50 IChSJkQpOi BHU0sgaW52 ZXN0cyBoZW F2aWx5IGlu IFImRCB0by BkZXZlbG9w IG5ldyBtZW RpY2luZXMs IHZhY2Npbm VzLCBhbmQg Y29uc3VtZX IgaGVhbHRo Y2FyZSBwcm 9kdWN0cy4g VGhlIGNvbX BhbnkgaGFz IHJlc2Vhcm NoIGNlbnRl cnMgYW5kIH BhcnRuZXJz aGlwcyB3b3 JsZHdpZGUg dG8gZHJpdm UgaW5ub3Zh dGlvbiBhbm QgaW1wcm92 ZSBwYXRpZW 50IGhlYWx0 aCBvdXRjb2 1lcy48YnI+ Mi4gQ29tbW VyY2lhbGl6 YXRpb24gYW 5kIE1hcmtl dGluZzogR1 NLIHNlbGxz IGl0cyBwcm 9kdWN0cyB0 byBwYXRpZW 50cywgaGVh bHRoY2FyZS Bwcm9mZXNz aW9uYWxzLC BhbmQgb3Ro ZXIgY3VzdG 9tZXJzIHRo cm91Z2ggYS B2YXJpZXR5 IG9mIGNoYW 5uZWxzLiBU aGlzIGluY2 x1ZGVzIHRy YWRpdGlvbm FsIHNhbGVz IGFuZCBtYX JrZXRpbmcg ZWZmb3J0cy wgYXMgd2Vs bCBhcyBkaW dpdGFsIGFu ZCBlLWNvbW 1lcmNlIGlu aXRpYXRpdm VzLjxicj4z LiBTdHJhdG VnaWMgUGFy dG5lcnNoaX BzOiBHU0sg Y29sbGFib3 JhdGVzIHdp dGggYSByYW 5nZSBvZiBw YXJ0bmVycy wgaW5jbHVk aW5nIGFjYW RlbWljIGlu c3RpdHV0aW 9ucywgYmlv dGVjaCBjb2 1wYW5pZXMs IGFuZCBvdG hlciBwaGFy bWFjZXV0aW NhbCBjb21w YW5pZXMsIH RvIGFkdmFu Y2UgaXRzIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCBlZmZvcn RzLjxicj40 LiBEaXZlcn NpZmllZCBQ b3J0Zm9saW 86IEdTSyBv cGVyYXRlcy BpbiB0aHJl ZSBtYWluIG FyZWFzIC0g cGhhcm1hY2 V1dGljYWxz LCB2YWNjaW 5lcywgYW5k IGNvbnN1bW VyIGhlYWx0 aGNhcmUuIF RoaXMgZGl2 ZXJzaWZpZW QgcG9ydGZv bGlvIGhlbH BzIG1pdGln YXRlIHJpc2 tzIGFuZCBh bGxvd3MgdG hlIGNvbXBh bnkgdG8gYm VuZWZpdCBm cm9tIHRoZS BkaWZmZXJl bnQgZ3Jvd3 RoIHRyZW5k cyBhbmQgcm VndWxhdG9y eSBsYW5kc2 NhcGVzIGFj cm9zcyB0aG VzZSBzZWN0 b3JzLjxicj 5JbiBhZGRp dGlvbiwgR1 NLIGhhcyBh IHN0cm9uZy Bmb2N1cyBv biBzdXN0YW luYWJpbGl0 eSBhbmQgc2 9jaWFsIHJl c3BvbnNpYm lsaXR5LCBp bnRlZ3JhdG luZyB0aGVz ZSBwcmluY2 lwbGVzIGlu dG8gaXRzIG J1c2luZXNz IG9wZXJhdG lvbnMgYW5k IGRlY2lzaW 9uLW1ha2lu Zy4gVGhlIG NvbXBhbnkg aXMgYWxzby Bjb21taXR0 ZWQgdG8gcH JpY2luZyBp dHMgcHJvZH VjdHMgcmVz cG9uc2libH kgYW5kIGVu c3VyaW5nIG FjY2VzcyB0 byBtZWRpY2 luZXMgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMu
Interesting facts about the company
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ“₯ Get our free eBook now: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3Mvbn VkRDBMNmt1 eFY4RFdsVX RKQjgud2Vi cCIgYWx0PS JHbGF4b1Nt aXRoS2xpbm UiIHRpdGxl PSJHbGF4b1 NtaXRoS2xp bmUiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2xh eG9TbWl0aE tsaW5lPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +GkyBEaXNj b3ZlciA8aT 4iVGhlIENo ZWNrbGlzdC BWYWx1ZSBJ bnZlc3Rvci DigJQgQSBT bWFydGVyIF dheSB0byBQ aWNrIFN0b2 NrcyI8L2k+ IOKAlCBmcm VlIGVCb29r IQogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8IS0t CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxkaXYg c3R5bGU9J2 1hcmdpbi10 b3A6IDEycH g7IGZvbnQt c2l6ZTogMT NweDsgY29s b3I6ICM0ND Q7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIFNpZ24g dXAgbm93IG FuZCBnZXQg b3VyIGZyZW UgZUJvb2sg CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICA8 Yj5UaGUgQ2 hlY2tsaXN0 IFZhbHVlIE ludmVzdG9y IOKAlCBBIF NtYXJ0ZXIg V2F5IHRvIF BpY2sgU3Rv Y2tzPC9iPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgLS0+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwhLS0KIC AgICAgICAg ICAgICAgIC AgICAgICAg PGRpdiBzdH lsZT0nbWFy Z2luLXRvcD ogMTZweDsg Zm9udC1zaX plOiAxNHB4 OyBjb2xvcj ogIzQ0NDsg Zm9udC1mYW 1pbHk6IC1h cHBsZS1zeX N0ZW0sIEJs aW5rTWFjU3 lzdGVtRm9u dCwgU2Vnb2 UgVUksIFJv Ym90bywgSG VsdmV0aWNh IE5ldWUsIH NhbnMtc2Vy aWY7IGxpbm UtaGVpZ2h0 OiAxLjY7Jz 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIE hhdmUgeW91 IGhlYXJkIG Fib3V0IG91 ciBzaG9ydC A8c3Ryb25n IHN0eWxlPS dmb250LXdl aWdodDogNj AwOyc+RGFp bHkgVmlkZW 8gTmV3c2xl dHRlcjwvc3 Ryb25nPj8K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIDxh IGhyZWY9J2 h0dHBzOi8v d3d3Lmluc2 lnaHRmdWx2 YWx1ZS5jb2 0vbmV3c2xl dHRlci5waH AnIHRhcmdl dD0nX2JsYW 5rJyBzdHls ZT0nY29sb3 I6ICMwMDdC RkY7IHRleH QtZGVjb3Jh dGlvbjogbm 9uZTsgZm9u dC13ZWlnaH Q6IDUwMDsg bWFyZ2luLW xlZnQ6IDZw eDsnPgogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIE ZpbmQgb3V0 IG1vcmUKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvYT 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIC0tPg ogICAgICAg ICAgICAgIC AgICAgIDwv ZGl2PgogIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICAK ICAgICAgIC AKICAgICAg ICA8c3Bhbi BjbGFzcz0n Ymx1cnJlZC 10ZXh0Jz4K ICAgICAgIC AgICAgTVM0 Z1IyeGhlRy A5VGJXbDBh RXRzIGFXNW xJR2x6SUcg RWdRbkpwZE dseiBhQ0J0 ZFd4MGFXID VoZEdsdmJt RnMgSUhCb1 lYSnRZVyBO bGRYUnBZMk ZzIElHTnZi WEJoYm4ga3 NJSGRwZEdn ZyBhR1ZoWk hGMVlYIEow WlhKeklHbH UgSUV4dmJt UnZiaSB3Z1 JXNW5iR0Z1 IFpDNDhZbk krTWkgNGdW R2hsSUdOdi BiWEJoYm5r Z2FHIEZ6SU dFZ2JHOXUg WnlCb2FYTj BiMyBKNUxD QmtZWFJwIG JtY2dZbUZq YXkgQjBieU JoSUhCbyBZ WEp0WVdONU lHIDl3Wlc1 bFpDQmkgZV NCS2IzTmxj RyBnZ1RtRj BhR0Z1IElH bHVJRTVsZH kgQmFaV0Zz WVc1ayBJR2 x1SURFNE16 IEF1UEdKeV BqTXUgSUZS b1pTQmpiMi Axd1lXNTVJ SGRoIGN5Qm 1iM0p0WVcg eHNlU0JtYj NWdSBaR1Zr SUdsdUlEIE U1TURZZ1lu a2cgU205el pYQm9JRSBW a2QyRnlaQ0 JPIFlYUm9Z VzRnWVcgNW tJR2hwY3lC aSBjbTkwYU dWeUxXIGx1 TFd4aGR5d2 cgVkdodmJX RnpJRSBodm JHeHZkMkY1 IExDQmhjeU JoSUggTnRZ V3hzSUhCby BZWEp0WVdO NUlHIGx1SU V4dmJtUnYg Ymk0OFluSS tOQyA0Z1ZH aGxJRzVoIG JXVWdSMnho ZUcgOGdZMj l0WlhNZyBa bkp2YlNCMG FHIFVnWm1s eWMzUWcgY0 hKdlpIVmpk QyBCMGFHRj BJSFJvIFpT QmpiMjF3WV cgNTVJSEJ5 YjJSMSBZMl ZrTENCM2FH IGxqYUNCM1 lYTWcgWVNC a2NtbGxaQy BCdGFXeHJJ SEJ5IGIyUj FZM1FnWTIg RnNiR1ZrSU VkcyBZWGh2 TGp4aWNqID QxTGlCSGJH RjQgYnlCdF pYSm5aVyBR Z2QybDBhQ0 JYIFpXeHNZ Mjl0WlMgQn BiaUF4T1Rr MSBJSFJ2SU dadmNtIDBn UjJ4aGVHOG cgVjJWc2JH TnZiVyBVc0 lIZG9hV05v IElIUm9aVz RnYlcgVnla MlZrSUhkcC BkR2dnVTIx cGRHIGhMYk dsdVpTQkMg WldWamFHRn RJRyBsdUlE SXdNREFnIG RHOGdabTl5 YlMgQkhiR0 Y0YjFOdCBh WFJvUzJ4cG JtIFV1UEdK eVBqWXUgSU Vkc1lYaHZV MiAxcGRHaE xiR2x1IFpT QnBjeUJqZF ggSnlaVzUw YkhrZyBiMj VsSUc5bUlI IFJvWlNCc1 lYSm4gWlhO MElIQm9ZWC BKdFlXTmxk WFJwIFkyRn NJR052Ylgg QmhibWxsY3 lCcCBiaUIw YUdVZ2QyID l5YkdRc0lI ZHAgZEdnZ2 NtVjJaVyA1 MVpTQnZaaU J2IGRtVnlJ Q1EwTVMgQm lhV3hzYVc5 dSBJR2x1SU RJd01qIEF1 UEdKeVBqY3 UgSUZSb1pT QmpiMiAxd1 lXNTVJR2x6 IElHRWdiV0 ZxYjMgSWdj SEp2WkhWai BaWElnYjJZ Z2RtIEZqWT JsdVpYTXMg SUdOdmJuTj FiVyBWeUlH aGxZV3gwIG FHTmhjbVVn Y0ggSnZaSF ZqZEhNcyBJ R0Z1WkNCd2 NtIFZ6WTNK cGNIUnAgYj I0Z2JXVmth VyBOcGJtVn pMQ0JoIGJt UWdhWFFnYU cgRnpJR0Vn Y0hKbCBjMl Z1WTJVZ2FX IDRnYjNabG NpQXggTlRB Z1kyOTFibi BSeWFXVnpM anhpIGNqND RMaUJIYkcg RjRiMU50YV hSbyBTMnhw Ym1VZ2FHIE Z6SUdFZ2JH OXUgWnlCb2 FYTjBiMyBK NUlHOW1JSE 5wIFoyNXBa bWxqWVcgNT BJSE5qYVdW dSBkR2xtYV dNZ1lXIE5v YVdWMlpXMW wgYm5SekxD QnBibSBOc2 RXUnBibWNn IGRHaGxJR1 JsZG0gVnNi M0J0Wlc1MC BJRzltSUhS eVpXIEYwYl dWdWRITWcg Wm05eUlFaE pWaSB3Z2FX NW1iSFZsIG JucGhMQ0Jo Ym0gUWdiV0 ZzWVhKcCBZ UzQ4WW5JK0 9TIDRnVkdo bElHTnYgYl hCaGJua2dh RyBGeklHRn NjMjhnIFlt VmxiaUJwYm 4gWnZiSFps WkNCcCBiaU J6WlhabGNt IEZzSUdocF oyZ3QgY0hK dlptbHNaUy BCc1pXZGhi Q0JqIFlYTm xjeXdnYVcg NWpiSFZrYV c1biBJR0Vn SkRNZ1ltIG xzYkdsdmJp QnogWlhSMG JHVnRaVyA1 MElHWnZjaU JwIGJHeGxa MkZzYkgga2 djSEp2Ylc5 MCBhVzVuSU dObGNuIFJo YVc0Z1pISj EgWjNNZ1lX NWtJRyBFZ2 MyVjBkR3hs IGJXVnVkQ0 IzYVggUm9J SFJvWlNCVi BVeUJuYjNa bGNtIDV0Wl c1MElHWnYg Y2lBa056VX dJRyAxcGJH eHBiMjRnIF ptOXlJRzFo Ym4gVm1ZV0 4wZFhKcCBi bWNnWVc1a0 lIIEYxWVd4 cGRIa2cgWT I5dWRISnZi QyBCd2NtOW liR1Z0IGN5 QmhkQ0JoSU ggQnNZVzUw SUdsdSBJRk IxWlhKMGJ5 IEJTYVdOdk xqeGkgY2o0 eE1DNGdTVy A0Z01qQXlN Q3dnIFIyeG hlRzlUYlcg bDBhRXRzYV c1bCBJR0ps WTJGdFpTIE IwYUdVZ1pt bHkgYzNRZ2 NHaGhjbSAx aFkyVjFkR2 xqIFlXd2dZ Mjl0Y0cgRn VlU0IwYnlC dyBiR1ZrWj JVZ2RHIDhn YldGclpTQn AgZEhNZ1ky RnlZbSA5dU lHWnZiM1J3 IGNtbHVkQ0 J1WlggUXRl bVZ5YnlCaS BlU0F5TURV d0xqIHhpY2 o0eE1TNGcg UjJ4aGVHOV RiVyBsMGFF dHNhVzVsIE lHaGhjeUJo SUggTjBjbT l1WnlCaiBi MjF0YVhSdF pXIDUwSUhS dklHTnYgY2 5CdmNtRjBa UyBCemIyTn BZV3dnIGNt VnpjRzl1Yz IgbGlhV3hw ZEhrcyBJSG RwZEdnZ1lT IEJtYjJOMW N5QnYgYmlC cGJYQnliMy BacGJtY2da Mnh2IFltRn NJR2hsWVcg eDBhQ3dnY2 1WayBkV05w Ym1jZ2FYIF J6SUdWdWRt bHkgYjI1dF pXNTBZVyB3 Z2FXMXdZV0 4wIExDQmhi bVFnYzMgVn djRzl5ZEds dSBaeUJqYj IxdGRXIDVw ZEdsbGN5Qj MgYUdWeVpT QnBkQyBCdm NHVnlZWFJs IGN5NDhZbk krTVQgSXVJ RlJvWlNCai BiMjF3WVc1 NUlHIGhoY3 lCaElHUnAg ZG1WeWMyVW dkMiA5eWEy WnZjbU5sIE xDQjNhWFJv SUcgOTJaWE lnTVRBdyBM REF3TUNCbG JYIEJzYjNs bFpYTWcgZD I5eWJHUjNh VyBSbElHRn VaQ0JoIElI TjBjbTl1Wn kgQm1iMk4x Y3lCdiBiaU JrYVhabGNu IE5wZEhrZ1 lXNWsgSUds dVkyeDFjMi BsdmJpQnBi aUIwIGFHVW dkMjl5YTMg QnNZV05sTG p4aSBjajR4 TXk0Z1IyIH hoZUc5VGJX bDAgYUV0c2 FXNWxJRyBo aGN5QmhJSE p2IFluVnpk Q0J3YVggQm xiR2x1WlNC diBaaUJ1Wl hjZ1pIIEox WjNNZ1lXNW sgSUhSeVpX RjBiVyBWdW RITWdhVzRn IFpHVjJaV3 h2Y0cgMWxi blFzSUhkcC BkR2dnYjNa bGNpIEExTU NCallXNWsg YVdSaGRHVW dkRyBobGNt RndhV1Z6IE lHbHVJSFpo Y20gbHZkWE 1nYzNSaCBa MlZ6SUc5bU lHIE5zYVc1 cFkyRnMgSU hSeWFXRnNj eSA0OFluSS tNVFF1IElG Um9aU0JqYj IgMXdZVzU1 SUdoaCBjeU JoSUhOMGNt IDl1WnlCd2 NtVnogWlc1 alpTQnZiaS BCemIyTnBZ V3dnIGJXVm thV0VzSUgg ZHBkR2dnYj NabCBjaUE0 TlN3d01EIE FnWm05c2JH OTMgWlhKek lHOXVJRiBS M2FYUjBaWE lnIFlXNWtJ R0ZqZEcgbD JaU0JoWTJO diBkVzUwY3 lCdmJpIEJN YVc1clpXUk ogYml3Z1Jt RmpaVyBKdm Iyc3NJR0Z1 IFpDQkpibk 4wWVcgZHlZ VzB1UEdKeS BQakUxTGlC SGJHIEY0Yj FOdGFYUm8g UzJ4cGJtVW dhRyBGeklI SmxZMlZwIG RtVmtJRzUx YlcgVnliM1 Z6SUdGMyBZ WEprY3lCaG JtIFFnY21W amIyZHUgYV hScGIyNGda bSA5eUlHbD BjeUIzIGIz SnJMQ0JwYm 0gTnNkV1Jw Ym1jZyBZbV ZwYm1jZ2Jt IEZ0WldRZ2 IyNWwgSUc5 bUlIUm9aUy BEaWdKeFhi M0pzIFpPS0 FtWE1nVFcg OXpkQ0JGZE docCBZMkZz SUVOdmJYIE JoYm1sbGMr S0EgblNCaW VTQjBhRyBV Z1JYUm9hWE 53IGFHVnla U0JKYm4gTj BhWFIxZEdV ZyBabTl5SU RFeElHIE52 Ym5ObFkzVj AgYVhabElI bGxZWCBKek xnPT0KICAg ICAgICA8L3 NwYW4+CiAg ICAgICAgCi AgICAgICAg
See Company Q&A
GlaxoSmithKline

πŸ“Š Get full analytics about GlaxoSmithKline

Sign up for free or log in

πŸ”“ Unlock our free guide: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal